Navigation Links
Cempra Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
Date:3/2/2011

CHAPEL HILL, N.C., March 2, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Cowen and Company 31st Annual Health Care Conference at 1:30 p.m. EST, March 7, 2011, at The Boston Marriott Copley Place in Boston.  Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin for community-acquired bacterial pneumonia and TAKSTATM for the oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA).

About Cempra PharmaceuticalsFounded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products' lifecycles. The company is also utilizing its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses in motilin receptor activity, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at www.cempra.com. Media Contacts:Robert E. Flamm, Ph.D.Russo Partners, LLC(212) 845-4226 Robert.flamm@russopartnersllc.comTony Russo, Ph.D.Russo Partners, LLC(212) 845-4251Tony.russo@russopartnersllc.com
'/>"/>

SOURCE Cempra Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
2. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
3. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
4. MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
5. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
7. Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
8. Anthera Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results and Operational Update
9. Savient Pharmaceuticals to Present at the Citi 2011 Global Healthcare Conference
10. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
11. Savient Pharmaceuticals Announces Executive Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Hill, Conn. (PRWEB) , ... April 28, 2016 ... ... of financing and ongoing support for Connecticut's innovative, growing companies, today announced the ... digital health and financial technology (fintech) companies. , “VentureClash looks to ...
(Date:4/27/2016)... ... , ... Cambridge Semantics, the leading provider of Smart Data analytic ... been named to The Silicon Review’s “20 Fastest Growing Big Data Companies of 2016.” ... the needs of end users facing some of the most complex data challenges in ...
(Date:4/27/2016)... , April 27, 2016 ... (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... an ihre Pressemitteilung vom 13. August 2015 die ... ihre Finanzen um zusätzliche 200.000.000 Einheiten auf 400.000.000 ... Dollar zu bringen. Davon wurden 157.900.000 Einheiten mit ...
(Date:4/27/2016)... ... 27, 2016 , ... PathSensors, Inc., a leading environmental testing ... will assist PathSensors in expanding the use of the company’s CANARY® technology in ... platform for the detection of harmful pathogens, including a number of bacteria, viruses, ...
Breaking Biology Technology:
(Date:3/22/2016)... OTTAWA, Ontario , PROVO ... 2016 Newborn Screening Ontario (NSO), which operates ... for molecular testing, and Tute Genomics and ... process management technology respectively, today announced the launch of ... new next-generation sequencing (NGS) testing panel. ...
(Date:3/18/2016)... , March 18, 2016 ... Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure ... & security companies in the border security market and the ... and Europe has led visiongain ... companies improved success. --> defence & security ...
(Date:3/15/2016)... ALBANY, New York , March 15, 2016 ... a new market report published by Transparency Market Research "Digital ... Growth, Trends and Forecast 2015 - 2023," the global digital ... at US$ 731.9 Mn in 2014 and is forecast to ... to 2023. Growth of micro, small and medium enterprises (MSMEs) ...
Breaking Biology News(10 mins):